您当前的位置:
首页 >
文章列表页 >
Engineered nucleus-free mesenchymal stem cells (MSCs) for the targeted delivery of therapeutics to disease site
更新时间:2023-05-16
    • Engineered nucleus-free mesenchymal stem cells (MSCs) for the targeted delivery of therapeutics to disease site

    • Genes & Diseases   Vol. 10, Issue 2, (2023)
    • 作者机构:

      1. Departments of Orthopaedic Surgery and Urology, The First Affiliated Hospital of Chongqing Medical University,Chongqing,China,400016

      2. School of Biomedical Engineering, Vanderbilt University,TN,Nashville,USA,37235

      3. Department of Clinical Laboratory Medicine, Shanghai Jiaotong University School of Medicine,Shanghai,China,200000

      4. Laboratory of Craniofacial Suture Biology and Development, Department of Surgery Section of Plastic Surgery, The University of Chicago Medical Center,IL,Chicago,USA,60637

      5. Molecular Oncology Laboratory, Department of Orthopedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center,IL,Chicago,USA,60637

    • DOI:10.1016/j.gendis.2022.09.001    

      CLC:
    • Published:2023,

      Published Online:1 March 2023,

    扫 描 看 全 文

  • Zander Schwartz, Piao Zhao, Annie Wang, et al. Engineered nucleus-free mesenchymal stem cells (MSCs) for the targeted delivery of therapeutics to disease site. [J]. Genes & Diseases 10(2).(2023) DOI: 10.1016/j.gendis.2022.09.001.

  •  
  •  
查看原文

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

No data

Related Author

No data

Related Institution

No data
0